5 companies in Longevity, privately held.
Cambrian Bio
Longevity · A group of companies developing drugs aimed at ageing biology
Latest (Jul 15, 2026): Cambrian Bio reports $123.8 million of equity sold in a private offering
Open profile →Life Biosciences
Longevity · Partial epigenetic reprogramming
Latest (Apr 24, 2026): Life Biosciences reports $31 million of equity sold in a private offering
Open profile →NewLimit
Longevity · Epigenetic reprogramming
Latest (May 15, 2025): NewLimit reports $129.8 million of equity sold in a private offering
Open profile →Rejuvenate Bio
Longevity · Gene & cell engineering · Gene therapy for ageing-related disease
Latest (Jun 18, 2026): Rejuvenate Bio reports $19.5 million of equity sold in a private offering
Open profile →Loyal (Cellular Longevity)
Longevity · Lifespan-extension drugs for dogs
No developments in the current window yet.
Open profile →Coverage is not an offer to invest. Private ownership does not imply available shares. Sector labels are Sapien Frontier’s own coverage classification, not company claims.
Missing a company? Request future coverage. We add a company when its filings, offering notices or awards can be followed reliably. See what we cover and how often.